BPC-157 Side Effects: What Women Need to Know About Potentially Permanent Risks

What Is BPC-157 and Why Are Women Asking About It?

BPC-157, formally called Body Protection Compound-157, is a synthetic 15-amino-acid peptide derived from a protein sequence found in human gastric juice. It has circulated on peptide-enthusiast forums and wellness social media as a supposed tissue-healing, gut-repair, and injury-recovery agent. Many women now encounter it through fitness communities, longevity clinics, and compounding pharmacies, often without any prescription or meaningful medical supervision.

The appeal is real. Women dealing with chronic gut conditions, sports injuries, tendon pain, or inflammatory conditions are genuinely underserved by conventional medicine. BPC-157 is marketed as a fix for all of these. The problem is that the entire evidence base consists of rodent and small-animal studies, mostly from one Croatian research group led by Predrag Sikiric, with a handful of small human case series that have never been replicated in controlled trials.

The FDA issued a safety alert in 2022 specifically warning consumers about compounded BPC-157 products, stating that BPC-157 has not been shown to be safe or effective and that its use may put patients at risk. That alert named BPC-157 as a substance that should not be compounded for human use.

No named phase II or phase III randomized controlled trial in humans has been published on PubMed for BPC-157 as of January 2025. This is not a minor evidentiary gap. It means every benefit claim and every dose recommendation you see online is extrapolated from rats, not from women.

Known and Reported Side Effects in Humans

Most reported human adverse events come from self-reporting on forums, compounding-pharmacy incident logs, and a small number of case reports, not from controlled studies.

Nausea, Dizziness, and Injection-Site Reactions

The most commonly self-reported short-term effects include nausea, dizziness, lightheadedness, and injection-site pain or swelling. A 2019 review of BPC-157 animal and human literature published in Current Pharmaceutical Design acknowledged these transient symptoms but noted that the human data were insufficient to characterize their true incidence or severity.

Injection-site reactions include redness, induration, and occasional bruising, which are expected with any subcutaneous peptide injection. These are generally short-lived. They are not the side effects that should worry you most.

Hormonal and Endocrine Signals

This is where women need to pay closer attention than men. BPC-157 has demonstrated interactions with dopaminergic, serotonergic, and nitric-oxide pathways in rodent models. A 2016 study in the Journal of Physiology-Paris showed that BPC-157 modulated dopamine and serotonin neurotransmitter activity in rats, systems that also regulate the hypothalamic-pituitary-gonadal (HPG) axis in women.

The HPG axis controls your menstrual cycle, ovarian function, estrogen and progesterone production, and fertility. Any compound that touches dopamine or serotonin signaling in the hypothalamus can, in principle, alter LH and FSH pulsatility, which changes your cycle. No study has directly measured this effect in women, but the mechanistic pathway is biologically plausible and should not be dismissed.

Women with PCOS already have disrupted HPG signaling and elevated LH-to-FSH ratios. Women in perimenopause have a HPG axis that is already destabilizing. For both groups, introducing an uncharacterized compound that affects these same pathways carries unknown but potentially significant risk.

Gastrointestinal Changes

Some users report changes in bowel habits, increased gut motility, or paradoxical gut discomfort, even though BPC-157 is most often marketed for gut healing. The data on gut effects come almost entirely from rat models of colitis and gastric ulcer, as documented in a 2018 review in Current Neuropharmacology. Extrapolating these findings to women with IBS, IBD, or endometriosis-related gut symptoms is a leap the existing literature does not support.

Potentially Permanent Side Effects: The Oncogenic Signal

This is the section that matters most, and it is where the evidence base, thin as it already is, carries the most serious warnings.

Tumor Promotion in Animal Models

Several rodent studies have raised a signal that BPC-157 may promote the growth of existing tumors rather than cause them de novo. A 2009 study in the Journal of Physiology-Paris found that BPC-157 accelerated tumor growth in mice that had been implanted with melanoma cells. The peptide did not appear to initiate cancer, but it appeared to promote angiogenesis, the growth of new blood vessels that feed tumor tissue.

Angiogenesis promotion is a particularly serious concern for women because several hormone-sensitive cancers, including breast cancer, endometrial cancer, and ovarian cancer, depend heavily on angiogenic signaling for growth and metastasis. Breast cancer is the most common cancer in women globally, affecting approximately 2.3 million women per year worldwide according to WHO data. Any compound with an angiogenic promotion signal in animal models warrants extreme caution in this population.

Why "Potentially Permanent" Is the Right Language

Most side effects from short-term peptide use resolve when you stop the compound. Oncogenic promotion does not work that way. If BPC-157 accelerates the growth of a pre-existing occult tumor, that effect does not reverse when you discontinue the peptide. The tumor continues to grow. By the time a woman notices symptoms, the disease may have progressed to a stage that is more difficult to treat.

This is why the word "permanent" applies here, even though BPC-157 itself leaves the body. The downstream biological consequence of having promoted tumor vascularization may be irreversible. No long-term follow-up data in humans exist to either confirm or definitively rule out this risk.

The FAERS Database: What Post-Market Surveillance Shows

The FDA Adverse Event Reporting System (FAERS) contains voluntary reports from consumers and clinicians. Because BPC-157 is not an approved drug, reports are categorized under dietary supplement or "other" compound adverse events. As of 2025, FAERS contains a limited number of reports associated with peptide products including BPC-157, largely reflecting the same GI, neurological, and injection-site events noted above. The low report count should not be interpreted as evidence of safety. It reflects the compound's unregulated status and the resulting underreporting infrastructure.

Fibrosis and Scarring Signals

A counterintuitive finding from some rodent studies is that while BPC-157 reduces fibrosis in injured tissue in certain models, it may promote fibrotic changes in other tissue contexts. A 2021 publication in Biomedicines noted that BPC-157 influenced extracellular matrix remodeling in ways that were context-dependent and not uniformly beneficial. For women with endometriosis, a condition characterized by exactly this kind of aberrant extracellular matrix remodeling, this signal is worth noting, even if the direct evidence does not yet exist.

Sex-Specific Pharmacokinetics: What We Do Not Know

Women process drugs differently than men across every pharmacokinetic domain. Women generally have lower body water content, higher body fat percentage, slower gastric motility (which affects oral peptide absorption), and different renal clearance rates. Hormonal fluctuations across the menstrual cycle alter liver enzyme activity, particularly CYP3A4, and change the volume of distribution for many compounds.

No pharmacokinetic study of BPC-157 has been conducted in women. The absorption, distribution, metabolism, and elimination of this peptide across the follicular and luteal phases, across pregnancy, across perimenopause, and in post-menopause is completely unknown. The NIH Office of Research on Women's Health has documented that sex as a biological variable affects drug response across virtually all therapeutic areas, yet BPC-157 research has never incorporated female animals consistently, let alone human women.

Dose recommendations circulating online (commonly 250 to 500 micrograms per day for subcutaneous injection, or 1 to 2 mg per day for oral use) are derived entirely from body-weight scaling of rat data. They have no validated basis in human female pharmacology.

How BPC-157 Interacts with Female Hormonal Conditions

PCOS

Women with PCOS have elevated androgen levels, insulin resistance, and disrupted LH pulsatility. Because BPC-157 may influence dopamine signaling, which in turn regulates GnRH and thus LH secretion, there is a theoretical risk of worsening the LH hypersecretion that characterizes PCOS. This has not been studied. Given that PCOS affects between 8 and 13 percent of reproductive-age women, according to WHO estimates, the absence of any safety data in this group is a meaningful gap.

Perimenopause and Menopause

The vasodilatory effects of BPC-157, mediated partly through nitric oxide pathways, could theoretically affect vasomotor symptoms like hot flashes, but there is no evidence to support a therapeutic role and no dose established for this use. Women in perimenopause have fluctuating estrogen levels that alter vascular tone. Adding an uncharacterized vasoactive peptide to this already shifting physiological state carries unpredictable risk.

Endometriosis and Fibroids

The angiogenesis-promoting signal in BPC-157 animal studies is directly relevant to endometriosis and uterine fibroids. Both conditions are driven in part by aberrant angiogenesis. Endometriosis affects roughly 10 percent of reproductive-age women globally, per WHO data. A compound that promotes new blood vessel growth could theoretically worsen both conditions. No direct study exists, but the mechanistic concern is real.

Female Pattern Hair Loss and Hormonal Acne

BPC-157 has been marketed anecdotally for hair regrowth and skin healing. The proposed mechanism involves growth factor upregulation. Given that female pattern hair loss and hormonal acne are both androgen-sensitive conditions that require precise hormonal management, adding a poorly characterized peptide with potential HPG axis effects is not a strategy supported by any evidence. The right tools for these conditions are medications with actual clinical trial data in women, such as spironolactone, finasteride (with strict contraception, detailed below), minoxidil, or oral contraceptives.

Pregnancy, Lactation, and Contraception Requirements

BPC-157 is contraindicated in pregnancy. This is not a cautious recommendation based on thin data. It is the correct position given the complete absence of human gestational safety data and the concerning signals from animal research.

Pregnancy Safety Data

No controlled study of BPC-157 in pregnant animals has been published with sufficient methodology to assess teratogenicity. The peptide's effects on angiogenesis, VEGF signaling, and growth factor pathways are all systems that are highly active and tightly regulated during placental development and fetal organogenesis. Placental angiogenesis is essential and precisely timed during the first trimester, as documented in research on trophoblast invasion and vascular development. Any exogenous compound that modifies VEGF or nitric oxide signaling during this window could theoretically disrupt placentation.

There is no pregnancy category assigned by the FDA because BPC-157 has never undergone the regulatory review process required for category assignment. The appropriate clinical default is: do not use in pregnancy.

Lactation Transfer

Transfer of BPC-157 into breast milk has not been studied. Peptides vary widely in their ability to pass into milk and in their oral bioavailability in the infant. Because the risk is unknown and the benefit in a lactating woman is unestablished, women who are breastfeeding should not use this compound.

Contraception Requirements

Because BPC-157 has unknown effects on the HPG axis and embryonic development, any woman of reproductive age who is sexually active and not planning pregnancy should use reliable contraception while using this compound. This is not a minor footnote. The theoretical HPG interactions mean that BPC-157 could, in principle, alter the efficacy of progestin-only contraceptives that depend on HPG suppression, though this has not been studied. Combined hormonal contraception or a long-acting reversible method (IUD or implant) would be preferable if a woman is considering this peptide despite the existing risk signals.

The stronger recommendation is to not use BPC-157 at all during reproductive years without a clearly documented clinical indication, supervised monitoring, and negative pregnancy test at baseline.

Who This Compound Is Not Right For (By Life Stage)

This section is intentionally framed around caution rather than indication, because no validated clinical indication exists for BPC-157 in women.

Trying to conceive. Avoid completely. Unknown effects on ovarian function, HPG axis, and early embryogenesis make this a clear contraindication.

Pregnant. Do not use. No safety data; biologically plausible risk through angiogenic and growth factor pathways.

Postpartum and breastfeeding. Do not use. Unknown milk transfer; no infant safety data.

Reproductive years with PCOS. High caution. Potential HPG interactions could worsen LH hypersecretion or alter cycle predictability.

Perimenopause. High caution. Vasoactive effects in the context of fluctuating estrogen are unpredictable. The HPG axis is already destabilizing.

Post-menopause. Caution. The oncogenic signal from animal studies remains relevant. Post-menopausal women already carry increased baseline risk for certain cancers; adding a compound with a tumor-promotion signal in rodents is unjustifiable without human safety data.

Personal or family history of breast, endometrial, or ovarian cancer. Do not use. The angiogenesis-promotion signal in animal studies is directly relevant and the risk-benefit calculation is clearly negative.

Active endometriosis or uterine fibroids. Avoid. Theoretical risk of promoting vascular growth in lesion tissue.

What Legitimate Research Looks Like Versus What Is Being Sold

The most frequently cited positive BPC-157 studies are preclinical. Sikiric and colleagues have published extensively in journals like Current Pharmaceutical Design and the Journal of Physiology-Paris on rodent models of gut injury, tendon repair, and neurological protection. These are real findings in animals. They do not constitute evidence of safety or efficacy in women.

A genuinely trustworthy clinical trial would need to include: a randomized placebo-controlled design, a human population with adequate female representation, standardized dosing with pharmacokinetic measurement, pre-specified safety endpoints including oncologic surveillance, and independent replication. None of these criteria are met by any published BPC-157 study as of 2025.

As WomanRx reviewer Dr. Maya Okafor, MD, puts it: "Women come to me having already purchased compounded BPC-157 online because they saw it promoted for gut healing or tendon recovery. My concern is not that they want better options for these problems. My concern is that they are taking a compound with a real tumor-promotion signal in animals, no human pharmacokinetic data, and no pregnancy safety information, and no one told them any of that before they paid for it."

The Evidence Gap Is Bigger for Women

The NIH did not require the inclusion of female cells and animals in preclinical research until 2016, following the passage of the NIH Revitalization Act and subsequent policy updates. Much of the BPC-157 rodent literature predates consistent female-animal inclusion. This means the positive healing data was often generated in male animals, and the safety signals (including tumor promotion) were also frequently observed in male animals. Neither set of results can be directly applied to women.

This is the evidence gap that WomanRx consistently names: the data is thin for everyone using BPC-157, but it is thinner still for women. When you hear that "studies show BPC-157 is safe," the honest translation is: "some studies in mostly male rats suggest certain effects; nothing has been studied in women."

If You Are Already Using BPC-157: What to Do Now

Stop and talk to your clinician before your next dose. Tell them the dose and route you have been using, how long you have been using it, and any symptoms you have noticed, including cycle changes, new GI symptoms, injection-site changes, or mood shifts.

If you have a personal or family history of any hormone-sensitive cancer, book an appointment within two weeks and disclose your use. Do not wait for your annual visit.

If you are trying to conceive and have been using BPC-157, stop immediately and discuss with your reproductive endocrinologist or OB-GYN. Take a pregnancy test if your period is late.

If you have been using BPC-157 throughout a menstrual cycle and notice irregularities, including missed periods, shortening or lengthening of your cycle, or changes in flow, bring this to your clinician. Cycle changes are not always benign in the context of an uncharacterized compound with HPG axis interactions.

The FDA's MedWatch reporting system allows you to report adverse events from dietary supplements and unapproved compounds. Reporting matters. The more cases that enter FAERS, the better the post-market safety signal becomes for this entire class of unregulated peptides.